Published in final edited form as:

Biol Psychiatry. 2011 April 1; 69(7): 618–624. doi:10.1016/j.biopsych.2010.11.011.

Chlorzoxazone, an SK channel activator used in humans, reduces excessive alcohol intake in rats

F. Woodward Hopf, Jeffrey A. Simms, Shao-Ju Chang, Taban Seif, Selena E. Bartlett, and Antonello Bonci

Ernest Gallo Clinic and Research Center (FWH, JAS, S-JC, SEB, AM), Program in Neuroscience (AB), and Department of Neurology (FWH, AB), University of California, San Francisco, California

Abstract

Background—Alcoholism imposes a tremendous social and economic burden. There are relatively few pharmacological treatments for alcoholism, with only moderate efficacy, and there is considerable interest in identifying additional therapeutic options. Alcohol exposure alters SK-type potassium channel (SK) function in limbic brain regions. Thus, positive SK modulators such as chlorzoxazone (CZX), an FDA-approved centrally-acting myorelaxant, might enhance SK function and decrease neuronal activity, resulting in reduced alcohol intake.

Methods—We examined whether CZX reduced alcohol consumption under two-bottle choice (20% alcohol and water) in rats with intermittent access to alcohol (IAA) or continuous access to alcohol (CAA). In addition, we used *ex vivo* electrophysiology to determine whether SK inhibition and activation can alter firing of nucleus accumbens (NAcb) core medium spiny neurons.

Results—CZX significantly and dose-dependently decreased alcohol but not water intake in IAA rats, with no effects in CAA rats. CZX also reduced alcohol preference in IAA but not CAA rats, and reduced the tendency for rapid initial alcohol consumption in IAA rats. CZX reduction of IAA drinking was not explained by locomotor effects. Finally, NAcb core neurons *ex vivo* showed enhanced firing, reduced SK regulation of firing, and greater CZX inhibition of firing in IAA versus CAA rats.

Conclusions—The potent CZX-induced reduction of excessive IAA alcohol intake, with no effect on the more moderate intake in CAA rats, may reflect the greater CZX reduction in IAA NAcb core firing observed *ex vivo*. Thus, CZX could represent a novel and immediately accessible pharmacotherapeutic intervention for human alcoholism.

Keywords

SK potassium channel; alcohol intake; intermittent; nucleus accumbens; neuro-adaptation

Address correspondence to F. Woodward Hopf, Ernest Gallo Clinic and Research Center, University of California, San Francisco, Dept. of Neurology, 5858 Horton St., Suite 200, Emeryville, CA, 94608, phone: 510-985-3892, fax: 510-985-3101, woody@gallo.ucsf.edu.

The authors report no biomedical financial interests or potential conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

There is considerable interest in identifying new pharmacological treatments for alcoholism, in part because of the enormous and deleterious health, economic, and/or societal consequences of alcoholism (1–4). There are several existing pharmacotherapies for alcoholism, including naltrexone and acamprosate, but these can have only moderate benefits or act in a subset of alcoholics (3). Thus, we and other labs have used rodent models to identify alcohol-related cellular neuro-adaptations that might represent novel therapeutic interventions for alcoholism.

In this regard, long-term, voluntary alcohol self-administration and withdrawal is associated with reduced function of SK-type calcium-activated potassium channels (SK) and increased excitability in neurons from the nucleus accumbens (NAcb) core (5), a region critical for regulation of reward-related and motivated behaviors (1,3,5–7), with no changes in NAcb core SK function or firing *ex vivo* after sucrose self-administration. Importantly, intra-NAcb core infusion of an SK activator, which depresses action potential firing, reduces alcohol- but not sucrose-seeking (5). In addition, no changes in SK function are seen in the NAcb shell or dorsal stratum, and SK activators in these regions do not alter alcohol intake (5). Thus, we hypothesize that NAcb core SK neuro-adaptations enhance alcohol intake, and allow SK activators to suppress alcohol intake. Also, passive alcohol exposure reduces SK function and increases excitability in the VTA (8), another limbic region that regulates alcohol intake (3,9). However, these studies suffer from several limitations, including the low alcohol intake during operant self-administration and the need to operantly respond to procure alcohol which is not present in human alcoholics, and the low face validity of passive exposure.

To better understand the relevance of SK neuro-adaptations for human alcoholism, we examined the impact of chlorzoxazone (CZX), an FDA-approved positive allosteric SK modulator (10) used for decades as a centrally-acting muscle relaxant (11), on alcohol intake in an intermittent access to alcohol (IAA) paradigm (12,13). Alcohol intake levels in IAA rats are significantly greater than in rats with continuous alcohol access (CAA) (12,13), and are more similar to intake levels in alcohol-preferring rat strains (14). In addition, alcohol intake in IAA rats continues despite pairing alcohol with the aversive quinine, suggesting that IAA alcohol intake has become inflexible or maladaptive relative to the quinine-sensitive alcohol intake in CAA rats (13,15). Also, several compounds which can reduce alcohol intake in human alcoholics have a greater effect on IAA versus CAA alcohol intake (12). Thus, the IAA model has predictive validity for human alcoholism, while the more moderate alcohol intake in CAA rats might better model social drinking.

Here, we show that CZX significantly reduced alcohol intake in IAA but not CAA rats. Also, NAcb core neurons *ex vivo* from IAA but not CAA rats showed reduced SK function, enhanced excitability, and increased sensitivity to inhibitory effects of CZX on firing. Thus, CZX may represent a novel and readily available pharmacotherapy for the treatment of human alcoholism.

Methods and Materials

Alcohol self-administration

Adult male, Wistar rats (250–275 g, Harlan, Livermore, CA) drank 20% alcohol or water under a two-bottle choice, home-cage, intermittent access to alcohol paradigm (IAA) modified from (12). Rats had 24 hour access to alcohol three days per week (starting Monday, Wednesday, and Friday) for 5–6 weeks. Rats were then switched to only 3 hours access to alcohol on the three days/week to simplify detection of CZX-related intake

changes. After 5–6 weeks of 3 hour/day, 3 day/week IAA drinking, the effects of CZX were examined.

Results from IAA rats were compared with rats with continuous access (24 hour/day, 7 days/week) to 20% alcohol and water under home-cage, two-bottle choice conditions (CAA), and CZX testing began after ~12 weeks CAA. CAA intake levels were measured in the same 3 hour period in which IAA rats had access to alcohol, and are only presented for the 3 hour consumption period due to the lower level of CAA alcohol consumption.

Alcohol drinking data were collected from 26 IAA rats and 19 CAA rats. Different doses of CZX were injected, once/week (Wednesday or Friday), in a counterbalanced manner across rats, with each rat receiving 3 of the 4 CZX doses (0, 10, 30, or 50 mg/kg). CZX was prepared in 25% cyclodextrin and 5% chremafluor, pH ~7.6, and injected i.p. 20–30 min before onset of access to alcohol.

Previous studies found that Wistar IAA rats show ~50 mg% (~10 mM) blood alcohol concentrations after 30 min alcohol access (12). Here, using previously published methods (12), IAA blood alcohol concentrations were 32.3 ± 7.5 mg% after 1 hour alcohol access ($n = 12$).

Ex vivo electrophysiology

Electrophysiology methods were as previously described (5). Briefly, rats were sedated with 40 mg/kg pentobarbital (i.p.) before transcardial perfusion with Ringers' solution containing (in mM): 225 sucrose, 119 NaCl, 2.5 KCl, 1.0 NaH_2PO_4 , 4.9 MgCl_2 , 0.1 CaCl_2 , 26.2 NaHCO_3 , 1.25 glucose, 1 ascorbic acid, 3 kynurenic acid. The brain was removed, and coronal slices (300 μm) cut in this same solution. Slices then recovered in 32°C carbogen-bubbled artificial cerebro-spinal fluid (aCSF) containing (in mM): 126 NaCl, 2.5 KCl, 1.2 NaH_2PO_4 , 1.2 MgCl_2 , 2.4 CaCl_2 , 18 NaHCO_3 , 11 glucose, pH 7.2–7.4, 301–305 mOsm. During electrophysiology experiments, slices were perfused with 31–32°C carbogen-bubbled aCSF and supplemented with CNQX (10 μM) and picrotoxin (50 μM) to block AMPA and GABA-A receptors.

Whole-cell current-clamp recordings were performed in medium spiny neurons, identified by small size, subthreshold depolarizing ramps with slow, repetitive firing, and resting potential less than -85 mV (16), using a Multiclamp 700A patch amplifier and pClamp9.2 (Axon Instruments, Union City, CA). The internal solution contained (in mM): 130 KOH, 105 methanesulfonic acid, 17 hydrochloric acid, 20 HEPES, 0.2 EGTA, 2.8 NaCl, 2.5 mg/ml MgATP , 0.25 mg/ml NaGTP . The resting membrane potential was brought to ~ -90 mV by passage of DC current before firing was generated with 300-msec depolarizing current pulses. For basal *ex vivo* electrophysiological differences between IAA and CAA rats, similar results were observed if all neurons across all rats were averaged together, or if all neurons from a given rat were averaged together to yield a single value for each rat (not shown).

Brain slices from IAA animals were prepared 24 to 48 hours after alcohol intake, a time point equivalent to when the animal would have access for self administration. Functional properties were not different at 24 versus 48 hours after drinking (not shown).

Reagents

CZX and apamin were from Sigma-Aldrich (St. Louis, MO).

Statistical Analysis

Statistics were calculated using an unpaired t-test, or a one-way or two-way ANOVA with Tukey post-hoc, using SigmaStat 3.1 (Systat Software, San Jose, CA).

Results

As shown in Figure 1, IAA rats were trained to drink 20% alcohol versus water under a two-bottle choice, home-cage, intermittent access to alcohol paradigm, while CAA rats had continuous access to 20% alcohol concurrent with water. CZX significantly and dose-dependently reduced alcohol drinking in IAA rats, determined after 3 hours access to alcohol (Figure 2A; $F_{(3,74)} = 17.45, p < .001$) or 1 hour access to alcohol (Figure 2C; $F_{(3,74)} = 20.63, p < .001$). Importantly, CZX did not significantly alter concurrent water intake in IAA rats after 3 hours (Figure 2B; $F_{(3,74)} = 1.15, p = .336$) or 1 hour access (Figure 2D; $F_{(3,74)} = 1.86, p = .144$). In strong contrast to IAA rats, CZX had no effect on alcohol intake in CAA rats (Figure 3A; $F_{(3,53)} = 1.00, p = .398$), determined only after 3 hour access because of the lower amount of alcohol consumed, or on CAA water intake (Figure 3B; $F_{(3,53)} = 1.63, p = .195$). Thus, CZX potently reduced alcohol intake in IAA rats, with no effect on alcohol intake in CAA rats or on water intake in IAA or CAA rats, suggesting that CZX effects on IAA alcohol intake occurred through a specific reduction of alcohol consumption rather than nonspecific motor effects.

The preference ratio, the amount of alcohol consumed relative to the total liquid (alcohol plus water) consumed, has been considered to reflect the motivational relevance of alcohol (1). Preference for alcohol was very high in IAA rats, and dose-dependently decreased by CZX (Figure 4A; $F_{(3,74)} = 7.24, p < .001$). In contrast, the preference ratio in CAA rats was lower than in IAA, and was not altered by CZX (Figure 4B; $F_{(3,53)} = 1.64, p = .191$). Thus, CZX only reduced alcohol preference in IAA rats.

We also examined the impact of CZX on alcohol or water consumption in the first hour of access relative to the entire period of access. IAA rats consumed the majority of alcohol within the first hour of the 3-hour access session, and CZX significantly reduced the proportion of total alcohol consumed within the first hour of access (Figure 5A; $F_{(3,74)} = 10.48, p < .001$). In addition, in CAA rats, CZX did not significantly alter the amount of alcohol consumed within the first hour relative to the 3 hour drinking period (Figure 5C; $F_{(3,53)} = 1.08, p = .364$), nor the amount of water consumed in the first hour relative to total water consumption (Figure 5D; $F_{(3,53)} = 1.59, p = .202$). Thus, CZX not only reduced the total alcohol consumed in IAA rats, but also altered the pattern of alcohol intake only in IAA rats.

Since IAA rats undergo periods of withdrawal, we examined whether CZX could reduce CAA alcohol intake after a 24 hour withdrawal from alcohol. 30 mg/kg CZX had no significant effect on CAA alcohol intake after withdrawal (vehicle: $.74 \pm .08$ g/kg in 3 hours, $n = 7$; CZX: $.60 \pm .09$ g/kg in 3 hours, $n = 7$; $t_{(12)} = 1.21, p = .248$), although CAA alcohol intake was increased after withdrawal relative to no withdrawal ($t_{(22)} = 2.69, p = .013$), consistent with the widely observed alcohol deprivation effect (1). Further, CZX did not alter alcohol preference (vehicle: $38.0 \pm 3.7\%$; CZX: $33.2 \pm 5.7\%$; $t_{(12)} = .685, p = .506$) or amount of alcohol consumed in the first hour relative to total (vehicle: $48.7 \pm 6.0\%$; CZX: $53.6 \pm 8.9\%$; $t_{(12)} = .457, p = .656$) in CAA rats after 24 hours withdrawal. Also, 24 hour withdrawal in CAA rats significantly enhanced preference ($t_{(22)} = 6.408, p < .001$) but not the timing of consumption ($t_{(22)} = .159, p < .875$) relative to no withdrawal. Thus, although withdrawal increased alcohol intake and preference in CAA rats, these data suggest that the differential effect of CZX on IAA and CAA alcohol intake may not reflect the experience of withdrawal *per se*.

To further examine whether CZX reduction of IAA alcohol intake might reflect non-specific motor effects, we examined the impact of CZX on open-field locomotion. As shown in Figure 6, CZX produced a dose-dependent decrease in locomotion in IAA rats and CAA, with a similar effect on locomotion in both groups (CZX: $F_{(1,35)} = 12.957, p < .001$; group: $F_{(1,35)} = .301, p = .587$; interaction: $F_{(1,35)} = .001, p = .999$; post-hoc $p < .01$ for 30 mg/kg CZX and $p > .4$ for 10 mg/kg CZX in both groups). Taken together with a lack of effect of 30 mg/kg CZX on IAA water intake and CAA water and alcohol intake, these results indicate that the CZX reduction in IAA alcohol intake reflected a specific effect on IAA alcohol consumption.

Previous studies suggest that the ability of SK activators to reduce alcohol intake is enabled by the presence of neuro-adaptations in SK channels within the NAc core, where NAc core SK currents are reduced after operant self-administration of alcohol but not sucrose, and SK activation within the NAc core reduces intake of alcohol but not sucrose (5). Thus, we examined whether the differential behavioral effects of CZX in IAA and CAA rats might be reflected in *ex vivo* excitability of NAc core neurons. Basal firing *ex vivo* was significantly elevated in NAc core neurons from IAA relative to CAA and alcohol-naïve rats (Figure 7C; $F_{(2,54)} = 4.809, p = .012$ at 200 pA; $F_{(2,53)} = 7.729, p = .001$ at 220 pA), or as input-output slope (see figure legend; Figure 7D; $F_{(2,54)} = 20.53, p < .001$). In addition, the enhancement of NAc core firing by the SK antagonist apamin (100 nM) was significantly smaller in IAA versus CAA and naïve rats (Figure 7A, E; $F_{(2,14)} = 16.93, p < .001$). These results strongly suggest that AP firing in NAc core neurons was only enhanced in IAA rats, and that increased excitability of IAA neurons was a consequence of reduced SK function.

We next examined CZX inhibition of NAc core firing *ex vivo*. 100 μ M but not 30 μ M CZX significantly reduced firing in both IAA and CAA neurons, but 100 μ M CZX produced a significantly greater inhibition of firing in IAA versus CAA NAc core neurons, and pre-exposure to apamin greatly reduced the CZX inhibition of firing in both groups (Figure 7B, F; group: $F_{(1,18)} = 5.884, p = .026$; with or without apamin pre-exposure: $F_{(1,18)} = 30.247, p < .001$; group $\times$ apamin: $F_{(1,18)} = 5.751, p = .028$; post-hoc $p < 0.01$ IAA vs CAA, $p < 0.05$ apamin block of CZX). Thus, CZX inhibited NAc core firing through activation of SK channels, with a significantly greater reduction in firing in IAA versus CAA NAc core neurons.

Discussion

The present study demonstrates that CZX, an FDA-approved SK activator (10) used for decades in humans as a centrally-acting myorelaxant (11), reduced excessive alcohol intake in IAA rats but not moderate alcohol intake in CAA rats. CZX significantly and dose-dependently decreased alcohol intake in IAA rats, with no effect on concurrent water intake. In contrast, CZX did not reduce alcohol or water intake in CAA rats; the lack of effect of CZX in CAA rats was not due to a floor effect, since adulteration of alcohol with quinine reduces CAA alcohol intake (13). CZX also reduced alcohol preference in IAA but not CAA rats. Further, IAA rats drank most alcohol within the first hour of the 3-hour access period, and CZX reduced this tendency for strong initial alcohol consumption. CZX reduction of IAA drinking did not reflect effects on motor activity. In addition, *ex vivo* electrophysiology experiments found enhanced basal firing in the NAc core neurons from IAA versus CAA and age-matched, alcohol-naïve rats. Increased IAA basal firing was associated with a smaller enhancement of firing by the SK blocker apamin, suggesting that increased excitability reflected reduced SK function. Furthermore, CZX inhibited firing in both IAA and CAA NAc core neurons, but the CZX inhibition of firing was significantly greater in IAA neurons. Thus, CZX selectively reduced the excessive alcohol intake in IAA rats but not the moderate alcohol intake in CAA rats, and differential sensitivity to CZX may result

from a neuro-adaptation in NAc core SK function only in IAA rats. CZX could therefore represent a novel and potent pharmacotherapeutic intervention for human alcoholism.

Although CZX reduced alcohol intake in IAA but not CAA rats, some caution may be warranted for differential CZX effects on preference and intake pattern. For example, higher preference in IAA rats may simply reflect the restricted access to alcohol, while CAA animals have no time constraints and thus may spread their drinking out across time, which could reduce apparent alcohol preference. Also, although weekly IAA and CAA alcohol intake is similar (with CAA rats drinking less per day but with access to alcohol more days per week), we describe IAA alcohol intake as excessive (14) since the amount consumed in a given session of access is greater in IAA versus CAA rats, and heavy intake within a session is considered a better model of human alcoholism (14,15), e.g., where intermittent but not continuous access produces aversion-resistant alcohol intake (13,15). Finally, IAA rats experience repeated withdrawal from alcohol while CAA rats do not. In this regard, CAA rats after 24 hour withdrawal increased alcohol intake and preference, although with no changes in intake pattern, but CZX did not reduce CAA alcohol intake after withdrawal from alcohol. These results suggest that the differential effects of CZX on IAA and CAA alcohol intake may not reflect withdrawal *per se*.

CZX is used in humans as a centrally acting muscle relaxant, and reduced IAA alcohol intake could reflect more general motor or motivational impairments (17,18). 30 mg/kg CZX produced a similar, strong locomotor inhibition in both groups, but this dose of CZX significantly decreased IAA alcohol intake with no significant effect on IAA water intake or CAA water or alcohol intake. Thus, open-field locomotion may represent an inadequate control for possible non-specific motor effects of CZX on home-cage alcohol intake. Instead, the lack of effect of CZX on CAA alcohol or water intake or IAA water intake may represent better internal controls, which suggest that the CZX reduction in IAA alcohol intake did not reflect motor impairment.

The primary metabolic pathway for CZX is the CYP2E1 cytochrome P450, and the effective concentration of CZX could be altered if alcohol influences CYP2E1 activity. Prolonged alcohol exposure can upregulate CYP2E1 activity (19–21), including in the brain (22), which could decrease CZX concentrations in alcohol-drinking rats. However, alcohol can act as a moderate competitive inhibitor of CYP2E1 (23) and increase CZX peak concentrations, although this effect would be more pronounced across time and less evident in the first several hours (24–26). We have not examined CZX metabolism here, in part because repeated blood collection would likely disrupt ongoing alcohol intake. However, 10 mg/kg CZX significantly decreased IAA alcohol intake, while 30 mg/kg CZX did not alter CAA alcohol intake. Thus, alcohol-related CYP2E1 changes are unlikely to explain the differential effect of CZX on IAA versus CAA alcohol intake.

In addition to the CZX reduction of alcohol intake only in IAA rats, we also observed decreased SK regulation of NAc core firing *ex vivo* only in IAA rats. Mesolimbic regions such as the NAc core can promote alcohol seeking and intake (3,5,9,27–29), and the human NAc can be activated by alcohol-related cues which induce cravings (30,31). Action potential firing is a predominant mechanism through which neurons transmit information, and NAc firing, e.g. in response to reinforcer-predictive cues (32–34), is thought to contribute to initiation of motivated and addictive behaviors (6,7,32,33). Interestingly, we found that basal NAc core firing *ex vivo* was enhanced in neurons from IAA rats relative to CAA and alcohol-naïve rats. In addition, the SK antagonist apamin produced a smaller increase in IAA versus CAA firing, suggesting that increased basal IAA excitability reflected reduced SK regulation of firing. Also, CZX activation of SK produced a greater inhibition of firing in IAA versus CAA NAc core neurons. We previously showed (5) that

operant alcohol self-administration is associated with reduced NAc core SK function and greater inhibition of firing by SK activators, with no changes in SK function in other striatal regions or in the NAc core of sucrose self-administering animals. Importantly, local infusion of an SK activator only decreased reward-seeking behavior under conditions where reduced SK function was observed *ex vivo*. Thus, we hypothesize that reduced SK function in the NAc core is required for SK activators to depress alcohol intake. Also, reduced SK function might be expected to decrease the ability of CZX to modulate firing. However, the smaller CZX inhibition of CAA firing may instead reflect a floor effect, where CZX inhibition of firing is more moderate under conditions of stronger basal SK function. Finally, alcohol-related SK changes are also seen in the VTA (8) and hippocampus (35), and thus we cannot rule out the possibility that CZX could reduce alcohol intake by acting in these or other brain regions.

Interestingly, NAc SK function is also altered after cocaine exposure, but with increased SK function in the NAc shell (36), in contrast to decreased SK function with alcohol in the NAc core. SK function is also reduced after several forms of learning (37,38), suggesting that SK might undergo plastic changes in relation to many types of salient events. One interesting possibility is that SK changes represent a homeostatic response (36). For example, increased SK after hyperactivation associated with cocaine might serve to reduce excitability, while, conversely, decreased SK function might occur in response to the depressive effects of alcohol.

Although we hypothesize that CZX reduces drinking by SK activation (10), CZX can also act on other ion channels, including the large- (BK) and intermediate-conductance calcium-activated potassium channels (10,39). However, the SK antagonist apamin prevented the CZX inhibition of NAc core firing *ex vivo*, suggesting a preeminent CZX action through SK. Other CZX effects are also more consistent with action on SK. CZX produces a similar reduction in burst firing in midbrain dopamine neurons as 1-EBIO (40,41), another SK channel activator which does not activate BK (42,43). Furthermore, CZX prevents contraction of the isolated aorta in a manner consistent with SK suppression of excitability (44). Thus, we consider it likely that CZX reduces IAA alcohol intake through activation of SK.

There are three SK subunits (SK1-SK3), and SK3 subunits are particularly abundant in the NAc, while SK1 is relatively uncommon in the striatum but highly enriched in areas like the hippocampus, and SK2 is distributed throughout the brain (45,46). If alcohol alters just one subunit, a compound selective for that subunit could be more efficacious than CZX with fewer nonspecific effects. In this regard, operant alcohol intake reduces NAc core SK function and decreases protein levels of the SK3 but not SK2 subunit (5), and there are relatively selective activators for SK3/SK2 versus SK1 (47) and for SK1 versus SK3/SK2 (48). The fact that CZX is already approved for use in humans makes it of immediate potential clinical utility, although SK subunit-selective compounds could represent better pharmacological therapies in the future.

SK activators dampen neuronal excitability, and thus have been considered possible therapeutic agents to treat episodic ataxia type-2 (49,50), epilepsy (51), Parkinson's disease (52), anxiety (53), and alcohol addiction (5). CZX may represent just such an agent. However, the SK activator 1-EBIO only counteracted seizure activity at relatively high doses that also produced motor impairments (51), and CZX has been considered only moderately effective as a centrally-acting muscle relaxant (11). In contrast, even quite low doses of 1-EBIO reduce burst firing in midbrain dopamine neurons (40), and CZX reduced IAA alcohol intake even at 10 mg/kg, which had little effect on locomotor activity. Thus, we

speculate that CZX could be more potent as an anti-drinking compound relative to the presently approved use as a centrally-acting myorelaxant.

One important concern for use of CZX in humans is a CZX-related, rare, idiopathic liver toxicity (54,55). Although the mechanism of CZX toxicity is unclear, CYP2E1 in the liver metabolizes CZX to OH-CZX (23,56,57). Interestingly, alcoholics who do not have CYP2E1 induction after alcohol drinking show less clinical and biochemical signs of liver disease relative to CYP2E1-induced alcoholics (58). Thus, CYP2E1 metabolism of CZX could contribute to CZX toxicity, and compounds that inhibit CYP2E1 activity (23,56) and prevent alcohol-related liver damage in rats (57) might reduce the risk of liver toxicity and also the CZX dose required for effective plasma levels (59). In addition, hepatotoxic effects of CZX in humans are considered quite rare (54,55), and agents such as statins present liver-related side effects, but the benefits to human health, as well as the presence of relatively inexpensive liver screens, has not precluded their widespread use in humans (60,61).

In conclusion, CZX, an FDA-approved positive allosteric SK modulator, significantly and selectively reduced the excessive alcohol intake in IAA rats, with no effect on the more moderate alcohol intake in CAA rats. *Ex vivo* electrophysiology experiments showed that IAA NAc core neurons exhibit reduced SK regulation of firing and increased excitability. Also, CZX produced a greater inhibition of firing *ex vivo* in IAA NAc core neurons, and we hypothesize that reduced NAc core SK function in IAA rats may allow SK activation by CZX to reduce alcohol intake. These results support the importance of SK channels in the regulation of alcohol intake, and the use of CZX as a novel, potent, and immediately accessible therapeutic intervention for alcoholism.

Acknowledgments

This work was supported by NIAAA RO1AA015358 (FWH) and funds provided by the State of California for medical research on alcohol and substance abuse through the University of California, San Francisco (SEB, AB), and Department of Defense Grant W81XWH-08-1-0016 (SEB).

References

1. Sanchis-Segura C, Spanagel R. Behavioural assessment of drug reinforcement and addictive features in rodents: an overview. *Addict Biol.* 2006; 11:2–38. [PubMed: 16759333]
2. Larimer ME, Palmer RS, Marlatt GA. Relapse prevention. An overview of Marlatt's cognitive-behavioral model. *Alcohol Res Health.* 1999; 23:151–60. [PubMed: 10890810]
3. Spanagel R. Alcoholism: a systems approach from molecular physiology to addictive behavior. *Physiol Rev.* 2009; 89:649–705. [PubMed: 19342616]
4. Harwood HJ, Fountain D, Livermore G. Economic costs of alcohol abuse and alcoholism. *Recent Dev Alcohol.* 1998; 14:307–30. [PubMed: 9751951]
5. Hopf FW, Bowers MS, Chang SJ, Chen BT, et al. Reduced nucleus accumbens SK channel activity enhances alcohol seeking during abstinence. *Neuron.* 2010; 65:682–94. [PubMed: 20223203]
6. Kalivas PW, McFarland K. Brain circuitry and the reinstatement of cocaine-seeking behavior. *Psychopharmacology.* 2003; 168:44–56. [PubMed: 12652346]
7. Everitt BJ, Robbins TW. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. *Nat Neurosci.* 2005; 8:1481–9. [PubMed: 16251991]
8. Hopf FW, Martin M, Chen BT, Bowers MS, et al. Withdrawal From Intermittent Ethanol Exposure Increases Probability of Burst Firing in VTA Neurons In Vitro. *J Neurophysiol.* 2007; 98:2297–310. [PubMed: 17699688]
9. Gonzales RA, Job MO, Doyon WM. The role of mesolimbic dopamine in the development and maintenance of ethanol reinforcement. *Pharmacol Ther.* 2004; 103:121–46. [PubMed: 15369680]

10. Cao Y, Dreixler JC, Roizen JD, Roberts MT, et al. Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. *J Pharmacol Exp Ther.* 2001; 296:683–9. [PubMed: 11181893]
11. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review. *J Pain Symptom Manage.* 2004; 28:140–75. [PubMed: 15276195]
12. Simms JA, Steensland P, Medina B, Abernathy KE, et al. Intermittent access to 20% ethanol induces high ethanol consumption in Long-Evans and Wistar rats. *Alcohol Clin Exp Res.* 2008; 32:1816–23. [PubMed: 18671810]
13. Hopf FW, Chang SJ, Sparta DR, Bowers MS, et al. Motivation for alcohol becomes resistant to quinine adulteration after 3–4 months of intermittent alcohol self-administration. *Alcohol Clin Exp Res.* 2010; 34:1565–73.
14. Bell RL, Rodd ZA, Lumeng L, Murphy JM, et al. The alcohol-preferring P rat and animal models of excessive alcohol drinking. *Addict Biol.* 2006; 11:270–88. [PubMed: 16961759]
15. Loi B, Lobina C, Maccioni P, Fantini N, et al. Increase in Alcohol Intake, Reduced Flexibility of Alcohol Drinking, and Evidence of Signs of Alcohol Intoxication in Sardinian Alcohol-Preferring Rats Exposed to Intermittent Access to 20% Alcohol. *Alcohol Clin Exp Res.* 2010 Epub ahead of print.
16. Hopf FW, Cascini MG, Gordon AS, Diamond I, et al. Cooperative activation of dopamine D1 and D2 receptors increases spike firing of nucleus accumbens neurons via G-protein betagamma subunits. *J Neurosci.* 2003; 23:5079–5087. [PubMed: 12832531]
17. Kaneko I, Fukumori Y, Fukuda T, Takeuchi Y. Influence of alpha-chloralose on muscle relaxant effect of chlorzoxazone in rats and pharmacodynamic analysis. *J Pharmacobiodyn.* 1989; 12:441–7. [PubMed: 2614638]
18. Kaneko I, Fukumori Y, Fukuda T, Takeuchi Y. Relation of disposition kinetics to pharmacological effect of intravenous administration of chlorzoxazone in rats. *J Pharmacobiodyn.* 1990; 13:367–73. [PubMed: 2231268]
19. Howard LA, Micu AL, Sellers EM, Tyndale RF. Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. *J Pharmacol Exp Ther.* 2001; 299:542–50. [PubMed: 11602665]
20. Zerilli A, Lucas D, Amet Y, Beauge F, et al. Cytochrome P-450 2E1 in rat liver, kidney and lung microsomes after chronic administration of ethanol either orally or by inhalation. *Alcohol Alcohol.* 1995; 30:357–65. [PubMed: 7545990]
21. Yue J, Khokhar J, Miksys S, Tyndale RF. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. *Eur J Pharmacol.* 2009; 609:88–95. [PubMed: 19285975]
22. Hipolito L, Sanchez-Catalan MJ, Polache A, Granero L. Induction of brain CYP2E1 changes the effects of ethanol on dopamine release in nucleus accumbens shell. *Drug Alcohol Depend.* 2009; 100:83–90. [PubMed: 18990514]
23. Loizou GD, Cocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. *Hum Exp Toxicol.* 2001; 20:321–7. [PubMed: 11530830]
24. Muzeeb S, Pasha MK, Basha SJ, Mullangi R, et al. Effect of 1-aminobenzotriazole on the in vitro metabolism and single-dose pharmacokinetics of chlorzoxazone, a selective CYP2E1 substrate in Wistar rats. *Xenobiotica.* 2005; 35:825–38. [PubMed: 16278194]
25. Baek HW, Bae SK, Lee MG, Sohn YT. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6-hydroxychlorzoxazone formation. *J Pharm Sci.* 2006; 95:2452–62. [PubMed: 16886191]
26. Ahn CY, Bae SK, Jung YS, Lee I, et al. Pharmacokinetic parameters of chlorzoxazone and its main metabolite, 6-hydroxychlorzoxazone, after intravenous and oral administration of chlorzoxazone to liver cirrhotic rats with diabetes mellitus. *Drug Metab Dispos.* 2008; 36:1233–41. [PubMed: 18378564]
27. Hodge CW, Samson HH, Chappelle AM. Alcohol self-administration: further examination of the role of dopamine receptors in the nucleus accumbens. *Alcohol Clin Exp Res.* 1997; 21:1083–1091. [PubMed: 9309321]

28. Rassnick S, Pulvirenti L, Koob GF. Oral ethanol self-administration in rats is reduced by the administration of dopamine and glutamate receptor antagonists into the nucleus accumbens. *Psychopharmacology*. 1992; 109:92–8. [PubMed: 1365677]
29. Chaudhri N, Sahuque LL, Cone JJ, Janak PH. Reinstated ethanol-seeking in rats is modulated by environmental context and requires the nucleus accumbens core. *Eur J Neurosci*. 2008; 28:2288–98. [PubMed: 19046372]
30. Modell JG, Mountz JM. Focal cerebral blood flow change during craving for alcohol measured by SPECT. *J Neuropsychiatry Clin Neurosci*. 1995; 7:15–22. [PubMed: 7711486]
31. Kareken DA, Claus ED, Sabri M, Dziedzic M, et al. Alcohol-related olfactory cues activate the nucleus accumbens and ventral tegmental area in high-risk drinkers: preliminary findings. *Alcohol Clin Exp Res*. 2004; 28:550–7. [PubMed: 15100605]
32. Nicola SM. The nucleus accumbens as part of a basal ganglia action selection circuit. *Psychopharmacology*. 2007; 191:521–50. [PubMed: 16983543]
33. Carelli RM, Wightman RM. Functional microcircuitry in the accumbens underlying drug addiction: insights from real-time signaling during behavior. *Curr Opin Neurobiol*. 2004; 14:763–8. [PubMed: 15582381]
34. Schultz W. Neural coding of basic reward terms of animal learning theory, game theory, microeconomics and behavioural ecology. *Curr Opin Neurobiol*. 2004; 14:139–47. [PubMed: 15082317]
35. Mulholland PJ, Hopf FW, Bukiya AN, Martin GE, et al. Sizing up ethanol-induced plasticity: the role of small and large conductance calcium-activated potassium channels. *Alcohol Clin Exp Res*. 2009; 33:1125–35. [PubMed: 19389201]
36. Ishikawa M, Mu P, Moyer JT, Wolf JA, et al. Homeostatic synapse-driven membrane plasticity in nucleus accumbens neurons. *J Neurosci*. 2009; 29:5820–31. [PubMed: 19420249]
37. Brosh I, Rosenblum K, Barkai E. Learning-induced modulation of SK channels-mediated effect on synaptic transmission. *Eur J Neurosci*. 2007; 26:3253–60. [PubMed: 18005060]
38. Seroussi Y, Brosh I, Barkai E. Learning-induced reduction in post-burst after-hyperpolarization (AHP) is mediated by activation of PKC. *Eur J Neurosci*. 2002; 16:965–9. [PubMed: 12372033]
39. Liu YC, Lo YK, Wu SN. Stimulatory effects of chlorzoxazone, a centrally acting muscle relaxant, on large conductance calcium-activated potassium channels in pituitary GH3 cells. *Brain Res*. 2003; 959:86–97. [PubMed: 12480161]
40. Ji H, Shepard PD. SK Ca²⁺-activated K⁺ channel ligands alter the firing pattern of dopamine-containing neurons in vivo. *Neuroscience*. 2006; 140:623–33. [PubMed: 16564639]
41. Matthews RT, McMillen BA, Speciale SG, Jarrah H, et al. Effects of zoxazolamine and related centrally acting muscle relaxants on nigrostriatal dopaminergic neurons. *Brain Res Bull*. 1984; 12:479–86. [PubMed: 6467036]
42. Zavala-Tecuapetla C, Aguilera MA, Lopez-Guerrero JJ, Gonzalez-Marin MC, et al. Calcium-activated potassium currents differentially modulate respiratory rhythm generation. *Eur J Neurosci*. 2008; 27:2871–84. [PubMed: 18445052]
43. Strobaek D, Teuber L, Jorgensen TD, Ahring PK, et al. Activation of human IK and SK Ca²⁺-activated K⁺ channels by NS309 (6,7-dichloro-1H-indole-2,3-dione 3-oxime). *Biochim Biophys Acta*. 2004; 1665:1–5. [PubMed: 15471565]
44. Dong DL, Luan Y, Feng TM, Fan CL, et al. Chlorzoxazone inhibits contraction of rat thoracic aorta. *Eur J Pharmacol*. 2006; 545:161–6. [PubMed: 16859676]
45. Sailer CA, Kaufmann WA, Marksteiner J, Knaus HG. Comparative immunohistochemical distribution of three small-conductance Ca²⁺-activated potassium channel subunits, SK1, SK2, and SK3 in mouse brain. *Mol Cell Neurosci*. 2004; 26:458–69. [PubMed: 15234350]
46. Stocker M, Pedarzani P. Differential distribution of three Ca(2+)-activated K(+) channel subunits, SK1, SK2, and SK3, in the adult rat central nervous system. *Mol Cell Neurosci*. 2000; 15:476–93. [PubMed: 10833304]
47. Hougaard C, Eriksen BL, Jorgensen S, Johansen TH, et al. Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca²⁺-activated K⁺ channels. *Br J Pharmacol*. 2007; 151:655–65. [PubMed: 17486140]

48. Hougaard C, Jensen ML, Dale TJ, Miller DD, et al. Selective activation of the SK1 subtype of human small-conductance Ca^{2+} -activated K^{+} channels by 4-(2-methoxyphenylcarbamoyloxymethyl)-piperidine-1-carboxylic acid tert-butyl ester (GW542573X) is dependent on serine 293 in the S5 segment. *Mol Pharmacol.* 2009; 76:569–78. [PubMed: 19515965]
49. Walter JT, Alvina K, Womack MD, Chevez C, et al. Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia. *Nat Neurosci.* 2006; 9:389–97. [PubMed: 16474392]
50. Alvina K, Khodakhah K. KCa Channels as Therapeutic Targets in Episodic Ataxia Type-2. *J Neurosci.* 2010; 30:7249–57. [PubMed: 20505091]
51. Anderson NJ, Slough S, Watson WP. In vivo characterisation of the small-conductance KCa (SK) channel activator 1-ethyl-2-benzimidazolinone (1-EBIO) as a potential anticonvulsant. *Eur J Pharmacol.* 2006; 546:48–53. [PubMed: 16925994]
52. Aumann TD, Gantois I, Egan K, Vais A, et al. SK channel function regulates the dopamine phenotype of neurons in the substantia nigra pars compacta. *Exp Neurol.* 2008; 213:419–30. [PubMed: 18680743]
53. Mitra R, Ferguson D, Sapolsky RM. SK2 potassium channel overexpression in basolateral amygdala reduces anxiety, stress-induced corticosterone secretion and dendritic arborization. *Mol Psychiatry.* 2009; 14:847–55. 827. [PubMed: 19204724]
54. Jackson J, Anania FA. Chlorzoxazone as a cause of acute liver failure requiring liver transplantation. *Dig Dis Sci.* 2007; 52:3389–91. [PubMed: 17390222]
55. Powers BJ, Cattau EL Jr, Zimmerman HJ. Chlorzoxazone hepatotoxic reactions. An analysis of 21 identified or presumed cases. *Arch Intern Med.* 1986; 146:1183–6. [PubMed: 3521519]
56. Eap CB, Schnyder C, Besson J, Savary L, et al. Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. *Clin Pharmacol Ther.* 1998; 64:52–7. [PubMed: 9695719]
57. Gouillon Z, Lucas D, Li J, Hagbjork AL, et al. Inhibition of ethanol-induced liver disease in the intragastric feeding rat model by chlormethiazole. *Proc Soc Exp Biol Med.* 2000; 224:302–8. [PubMed: 10964266]
58. Dupont I, Bodenez P, Berthou F, Simon B, et al. Cytochrome P-450 2E1 activity and oxidative stress in alcoholic patients. *Alcohol Alcohol.* 2000; 35:98–103. [PubMed: 10684785]
59. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. *Clin Pharmacol Ther.* 1993; 53:643–50. [PubMed: 8513656]
60. Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. *Semin Liver Dis.* 2009; 29:412–22. [PubMed: 19826975]
61. Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. *Curr Treat Options Cardiovasc Med.* 2009; 11:272–8. [PubMed: 19627660]
62. Hopf FW, Seif T, Mohamedi ML, Chen BT, et al. The small-conductance calcium-activated potassium channel is a key modulator of firing and long-term depression in the dorsal striatum. *Eur J Neurosci.* 2010; 31:1946–59. [PubMed: 20497469]

A Intermittent Access to Alcohol drinking schedule (IAA)

B Continuous Access to Alcohol drinking schedule (CAA)

Figure 1.

Intermittent and Continuous Access to Alcohol intake paradigms. Adult, male Wistar rats were trained to drink 20% alcohol versus water under a two-bottle choice paradigm with (A) intermittent or (B) continuous access to alcohol (IAA or CAA, respectively). IAA rats had 24-hr access to alcohol three d/wk (starting Monday, Wednesday, and Friday) for 5–6 wk. Rats were then switched so that they only had 3 hr access to alcohol on the three d/wk to simplify detection of potential changes in intake after CZX. After 5–6 wk of 3 hr/d IAA drinking, the effects of CZX were examined. Different doses of CZX were injected, once per wk, 20–25 min before access to alcohol, in a counterbalanced manner across rats. Results from IAA rats were compared with CAA rats that had continuous access to 20% alcohol versus water for an equivalent period of drinking, so that CZX testing began after ~12 wks of CAA. CAA rats were allowed access to alcohol 24 hr/d 7d/wk, but alcohol intake levels

for this study were determined in the same 3 hr period in which IAA rats were allowed access to alcohol.

Figure 2.

CZX decreased IAA alcohol but not water intake. (**A, B**) CZX dose-dependently decreased IAA alcohol intake, determined after 3 hr access (**A**), with no effect on IAA water intake (**B**) (vehicle: $n = 22$; 10 mg/kg CZX: $n = 21$; 30 mg/kg CZX: $n = 22$; 50 mg/kg CZX: $n = 13$). Similarly, (**C, D**) CZX dose-dependently decreased IAA alcohol intake across 1 hr access (**C**) with no effect on water intake (**D**). In (**A**) and (**C**), post-hoc $p < .05$, 10 mg/kg vs 30 or 50 mg/kg CZX. * $p < .05$, ** $p < .01$ vs vehicle.

Figure 3.

CZX did not decrease CAA alcohol intake. CZX had no effect on alcohol (A) or water (B) intake in CAA rats (vehicle: $n = 17$; 10 mg/kg CZX: $n = 15$; 30 mg/kg CZX: $n = 16$; 50 mg/kg CZX: $n = 9$). CAA rats were allowed access to alcohol 24 hr/d 7d/wk, but alcohol intake levels were determined in the same 3 hr period in which IAA rats were allowed access to alcohol.

Figure 4.

Alcohol preference across the 3 hr of intake was decreased by CZX in IAA but not CAA rats. (**A, B**) CZX decreased the alcohol preference (the level of alcohol intake divided by the level of alcohol plus water intake) in IAA (**A**) but not CAA (**B**) rats. * $p < .05$ vs vehicle.

Figure 5.

IAA rats consumed most alcohol within the first hr of access. **(A)** IAA rats consumed most alcohol within the first hr of access, relative to the amount consumed across all 3 hr of access. CZX significantly reduced this higher initial consumption in IAA rats. **(B)** CZX did not alter water intake in IAA rats. CZX did have an overall significant effect on the pattern of IAA water consumption ($F_{(3,74)} = 4.25, p = .008$), but this reflected a significant difference post-hoc between 30 and 50 mg/kg rather than differences between any CZX dose and vehicle. **(C, D)** CZX did not alter the percent of total alcohol **(C)** or water **(D)** consumed in the first hr of access, relative to all 3 hr of access, in CAA rats. * $p < .05$ vs vehicle.

Figure 6.

CZX similarly depressed open-field locomotion in IAA rats (vehicle: $n = 10$; 10 mg/kg CZX: $n = 9$; 30 mg/kg CZX: $n = 6$) and CAA rats (vehicle: $n = 9$; 10 mg/kg CZX: $n = 9$; 30 mg/kg CZX: $n = 6$). Similar results were observed for stereotypies (not shown). * $p < .05$ vs vehicle.

Figure 7.

Ex vivo whole-cell patch-clamp electrophysiology experiments in NAc core neurons from IAA and CAA rats. **(A)** Examples showing that SK channel inhibition with apamin (100 nM) produced a smaller enhancement of firing in IAA vs CAA neurons, and that the CZX reduction in firing was prevented by apamin exposure in both IAA and CAA neurons. **(B)** Examples showing greater CZX inhibition of firing in IAA versus CAA neurons. **(C)** Greater basal excitability, measured with applied current versus action potential generation, was observed in IAA compared with CAA or naive NAc core neurons *ex vivo* (CAA: $n = 19$; naive: $n = 21$; IAA: $n = 17$). To generate firing, neurons were depolarized with a series of 7 or 8 300-msec current pulses, with 20 pA between each current pulse, where the initial current pulse for each neuron was just sub-threshold for firing. For one naive cell, firing was not determined at 220 pA. **(D)** Greater basal excitability measured with the input-output slope, calculated by fitting a line relating the number of APs generated in the first three supra-threshold current pulses and the last sub-threshold current pulse in a given neuron (5,62). **(E)** Decreased apamin enhancement of firing in IAA compared with CAA or naive NAc core neurons *ex vivo* (CAA: $n = 8$; naive: $n = 5$; IAA: $n = 7$). **(F)** CZX produced a greater inhibition of firing in IAA neurons ($n = 6$ for 100 μ M CZX and 4 for 30 μ M CZX for both groups), and CZX inhibited firing in IAA and CAA NAc core neurons through SK

channels, since the CZX reduction in firing was blocked by apamin ($n = 5$ for both groups). Example traces were from a current step to 140 pA for IAA and 140 pA for CAA in (**A**) and 120 pA for IAA and 180 pA for CAA in (**B**). * $p < .05$, ** $p < .01$, IAA vs CAA and naive.